Fig. 3

The effect of b-cyclodextrin-containing pharmaceutical agents on firefly luminescence output. a luminescence and b) fluorescence levels of cultured E0771 cells expressing both firefly luciferase and niRFP713 reporters. Cells were cultured and BLI/FLI measurements were performed in the presence or absence of voriconazole given 30 min prior to the measurement. C-f Relative 3D luminescence (c,e) or 3D fluorescence (d,f) of C57Bl6 mice having received E0771 cells expressing both firefly luciferase and niRFP713 reporters 5 days previously through hemodynamic perfusion, resulting in high levels of cells in the liver (day 1). Luminescence and niRFP713 signal was measured when d-luciferin was provided at 150 mg/kg body weight (normal dose, c) or under restrictive (low dose, e) conditions at 30 mg/kg body weight. The animals were treated with voriconazole (40 mg/kg via tail vein injection) 30 min prior to the second measurement (day 4). Data are expressed as violin plots (n = 6). Significant differences between (a,b) the voriconazole and non-voriconazole conditions or (c-f) D1 and D4 were analysed using GraphPad Prism 10 using a standard t-test with the degree of significance indicated when appropriate (*: p < 0.05)